API
< Back to all clusters
[BUSINESS] · Brazil, India · 5 sources

started · updated

Dr Reddy’s Laboratories receives Brazil approval for generic Ozempic

Indian pharmaceutical company Dr Reddy’s Laboratories has secured marketing authorization from Brazil’s National Health Surveillance Agency (ANVISA) to sell a generic version of semaglutide. The once-weekly medication is intended for adults with type 2 diabetes mellitus that is insufficiently controlled by diet and exercise alone.

The drug will be available in 2 mg and 4 mg doses via a pre-filled injector pen. Dr Reddy’s plans to launch the product in Brazil in collaboration with the Brazilian pharmaceutical company Aché. This move targets a significant market, as Brazil ranks sixth globally for diabetes prevalence, with approximately 16.6 million adults aged 20 to 79 living with the condition.

This approval follows a previous denial in April when the application failed to meet certain regulatory requirements. Dr Reddy’s has identified generic semaglutide as a major growth driver and is targeting further launches in Latin America and Africa in the coming months.

Entities

Aché · Anvisa · Brazil · Dr Reddy’s Laboratories · Novo Nordisk